Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson’s disease
NeuroImage: Clinical. 2022-01-01; 36: 103231
DOI: 10.1016/j.nicl.2022.103231
Read on PubMed
Khedher L(1), Bonny JM(2), Marques A(3), Durand E(3), Pereira B(4), Chupin M(5), Vidal T(3), Chassain C(3), Defebvre L(6), Carriere N(6), Fraix V(7), Moro E(7), Thobois S(8), Metereau E(8), Mangone G(9), Vidailhet M(9), Corvol JC(9), Lehéricy S(9), Menjot de Champfleur N(10), Geny C(11), Spampinato U(12), Meissner W(13), Frismand S(14), Schmitt E(14), Doé de Maindreville A(15), Portefaix C(16), Remy P(17), Fénelon G(17), Luc Houeto J(18), Colin O(19), Rascol O(20), Peran P(20), Durif F(3); R study group.
Author information:
(1)University Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal,
Clermont-Ferrand, France; AgroResonance, INRAE, 2018. Nuclear Magnetic Resonance
Facility for Agronomy, Food and Health, doi: 10.15454/1.5572398324758228E12,
France. Electronic address: .
(2)AgroResonance, INRAE, 2018. Nuclear Magnetic Resonance Facility for Agronomy,
Food and Health, doi: 10.15454/1.5572398324758228E12, France; AgroResonance
UR370 QuaPA – INRAE, Saint-Genès-Champanelle 63122, France.
(3)University Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal,
Clermont-Ferrand, France; Clermont-Ferrand University Hospital, Neurology
Department and NS-PARK/FCRIN Network, Clermont-Ferrand, France.
(4)Clermont-Ferrand University Hospital, Biostatistics Unit (DRCI),
Clermont-Ferrand, France.
(5)Sorbonne Université, Institut du Cerveau – ICM, CATI, Assistance Publique
Hôpitaux de Paris, Inserm, CNRS, Département de Neurologie and NS-PARK/FCRIN
Network, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
(6)Department of Movement Disorder and NS-PARK/FCRIN Network, Inserm 1172
University of Lille, Lille, France.
(7)Service de Neurologie, CHU de Grenoble and NS-PARK/FCRIN Network, Université
Grenoble Alpes, Grenoble Institute of Neuroscience, Grenoble, France.
(8)CNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229 CNRS, Lyon,
France; Université Claude Bernard, Lyon I, Lyon, France; Hospices Civils de
Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C and
NS-PARK/FCRIN Network, Lyon, France.
(9)Sorbonne Université, Institut du Cerveau – ICM, Assistance Publique Hôpitaux
de Paris, Inserm, CNRS, Département de Neurologie and NS-PARK/FCRIN Network, CIC
Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
(10)Department of Neuroradiology, Montpellier University Hospital Center, Gui de
Chauliac Hospital, Montpellier, France; I2FH, Institut d’Imagerie Fonctionnelle
Humaine, Hôpital Gui de Chauliac, CHRU de Montpellier, Montpellier, France.
(11)Department of Geriatrics and NS-PARK/FCRIN Network, Montpellier University
Hospital, Montpellier University, Montpellier, France; EuroMov Laboratory,
University of Montpellier, 700 Avenue du Pic Saint Loup, Montpellier,
Montpellier 34090, France.
(12)Service de Neurologie – Maladies Neurodégénératives and NS-PARK/FCRIN
Network, CHU Bordeaux, Bordeaux F-33000, France.
(13)Service de Neurologie – Maladies Neurodégénératives and NS-PARK/FCRIN
Network, CHU Bordeaux, Bordeaux F-33000, France; Univ. Bordeaux, CNRS, IMN, UMR
5293, Bordeaux, Bordeaux F-33000, France; Dept. Medicine, University of Otago,
Christchurch, and New Zealand Brain Research Institute, Christchurch, New
Zealand.
(14)Service de Neurologie and NS-PARK/FCRIN Network, CHRU-Nancy, Nancy, France.
(15)Department of Neurology and NS-PARK/FCRIN Network, Hôpital Maison blanche,
Reims, France.
(16)Department of Radiology, Hôpital Maison blanche, Reims, France; CReSTIC
Laboratory (EA 3804), University of Reims Champagne-Ardenne, Reims, France.
(17)Centre Expert Parkinson and NS-PARK/FCRIN Network, CHU Henri Mondor, AP-HP
et Equipe Neuropsychologie Interventionnelle, INSERM-IMRB, Faculté de Santé,
Université Paris-Est Créteil et Ecole Normale Supérieure Paris Sorbonne
Université, Créteil, France.
(18)INSERM, CHU de Poitiers, Université de Poitiers, Centre d’Investigation
Clinique CIC1402, Service de Neurologie and NS-PARK/FCRIN Network, Poitiers,
France – CHU – Centre Expert Parkinson de Limoges, Limoges, France.
(19)INSERM, CHU de Poitiers, Université de Poitiers, Centre d’Investigation
Clinique CIC1402, Service de Neurologie and NS-PARK/FCRIN Network, Poitiers,
France- CH Brive la Gaillarde, France.
(20)Centre d’Investigation Clinique CIC 1436, UMR 1214 TONIC and NS-PARK/FCRIN
Network, INSERM, CHU de Toulouse et Université de Toulouse3, Toulouse, France.
Several postmortem studies have shown iron accumulation in the substantia nigra
of Parkinson’s disease patients. Iron concentration can be estimated via MRI-R2∗
mapping. To assess the changes in R2∗ occurring in Parkinson’s disease patients
compared to controls, a multicentre transversal study was carried out on a large
cohort of Parkinson’s disease patients (n = 163) with matched controls (n = 82).
In this study, 44 patients and 11 controls were removed due to motion artefacts,
21 patient and 6 controls to preserve matching. Thus, 98 patients and 65 age and
sex-matched healthy subjects were selected with enough image quality. The study
was conducted on patients with early to late stage Parkinson’s disease. The
images were acquired at 3Tesla in 12 clinical centres. R2∗ values were measured
in subcortical regions of interest (substantia nigra, red nucleus, striatum,
globus pallidus externus and globus pallidus internus) contralateral (dominant
side) and ipsilateral (non dominant side) to the most clinically affected
hemibody. As the observed inter-subject R2∗ variability was significantly higher
than the disease effect, an original strategy (intrasubject subcortical
quantitative referencing, ISQR) was developed using the measurement of R2∗ in
the red nucleus as an intra-subject reference. R2∗ values significantly
increased in Parkinson’s disease patients when compared with controls; in the
substantia nigra (SN) in the dominant side (D) and in the non dominant side
(ND), respectively (PSN_D and PSN_ND